S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
S&P 500   4,397.94
DOW   34,265.37
QQQ   351.69
NASDAQ:NEO

NeoGenomics Stock Forecast, Price & News

$21.59
-0.29 (-1.33%)
(As of 01/21/2022 12:00 AM ET)
Add
Compare
Today's Range
$21.32
$22.25
50-Day Range
$21.59
$40.97
52-Week Range
$21.32
$61.57
Volume
1.64 million shs
Average Volume
1.08 million shs
Market Capitalization
$2.66 billion
P/E Ratio
59.97
Dividend Yield
N/A
Beta
0.63
30 days | 90 days | 365 days | Advanced Chart
Receive NEO News and Ratings via Email

Sign-up to receive the latest news and ratings for NeoGenomics and its competitors with MarketBeat's FREE daily newsletter.


NeoGenomics logo

About NeoGenomics

NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Testing laboratories
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NEO
Employees
1,700
Year Founded
N/A

Sales & Book Value

Annual Sales
$444.45 million
Cash Flow
$0.38 per share
Book Value
$6.25 per share

Profitability

Net Income
$4.17 million
Pretax Margin
7.57%

Debt

Price-To-Earnings

Miscellaneous

Free Float
117,335,000
Market Cap
$2.66 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
1/22/2022
Next Earnings (Estimated)
2/23/2022
Fiscal Year End
12/31/2022

MarketRank

Overall MarketRank

2.54 out of 5 stars

Medical Sector

111th out of 1,418 stocks

Testing Laboratories Industry

1st out of 1 stocks

Analyst Opinion: 4.5Community Rank: 4.9Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












NeoGenomics (NASDAQ:NEO) Frequently Asked Questions

Is NeoGenomics a buy right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NeoGenomics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NeoGenomics stock.
View analyst ratings for NeoGenomics
or view top-rated stocks.

How has NeoGenomics' stock price been impacted by COVID-19 (Coronavirus)?

NeoGenomics' stock was trading at $24.78 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, NEO shares have decreased by 12.9% and is now trading at $21.59.
View which stocks have been most impacted by COVID-19
.

When is NeoGenomics' next earnings date?

NeoGenomics is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for NeoGenomics
.

How were NeoGenomics' earnings last quarter?

NeoGenomics, Inc. (NASDAQ:NEO) issued its quarterly earnings data on Thursday, November, 4th. The medical research company reported ($0.08) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.09) by $0.01. The medical research company had revenue of $121.30 million for the quarter, compared to analyst estimates of $125.09 million. NeoGenomics had a net margin of 10.08% and a negative trailing twelve-month return on equity of 1.33%. The business's revenue for the quarter was down 3.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.04 earnings per share.
View NeoGenomics' earnings history
.

What guidance has NeoGenomics issued on next quarter's earnings?

NeoGenomics updated its FY 2021 earnings guidance on Thursday, November, 18th. The company provided earnings per share (EPS) guidance of $-0.290-$-0.250 for the period, compared to the Thomson Reuters consensus EPS estimate of $-0.210. The company issued revenue guidance of $482.50 million-$487.50 million, compared to the consensus revenue estimate of $497.53 million.

What price target have analysts set for NEO?

10 analysts have issued 12 month target prices for NeoGenomics' shares. Their forecasts range from $41.00 to $65.00. On average, they expect NeoGenomics' stock price to reach $51.40 in the next twelve months. This suggests a possible upside of 138.1% from the stock's current price.
View analysts' price targets for NeoGenomics
or view top-rated stocks among Wall Street analysts.

Who are NeoGenomics' key executives?

NeoGenomics' management team includes the following people:
  • Mark Mallon, Chief Executive Officer & Director
  • George A. Cardoza, President & Chief Operating Officer-Lab Operations (LinkedIn Profile)
  • Kathryn B. McKenzie, Chief Financial Officer
  • Steven A. Ross, Chief Information Officer & Vice President
  • John Mooney, Chief Technology Officer

What is Douglas M. VanOort's approval rating as NeoGenomics' CEO?

116 employees have rated NeoGenomics CEO Douglas M. VanOort on Glassdoor.com. Douglas M. VanOort has an approval rating of 98% among NeoGenomics' employees. This puts Douglas M. VanOort in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of NeoGenomics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NeoGenomics investors own include Marvell Technology (MRVL), NVIDIA (NVDA), Alibaba Group (BABA), Square (SQ), Inseego (INSG), PayPal (PYPL), Micron Technology (MU), Invitae (NVTA), CRISPR Therapeutics (CRSP) and AbbVie (ABBV).

What is NeoGenomics' stock symbol?

NeoGenomics trades on the NASDAQ under the ticker symbol "NEO."

Who are NeoGenomics' major shareholders?

NeoGenomics' stock is owned by a number of retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.22%), Exchange Traded Concepts LLC (0.09%), State of Alaska Department of Revenue (0.07%), Crossmark Global Holdings Inc. (0.02%), Lindbrook Capital LLC (0.00%) and HighMark Wealth Management LLC (0.00%). Company insiders that own NeoGenomics stock include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Jennifer Balliet, Kathryn B Mckenzie, Kevin C Johnson, Lawrence Martin Weiss, Mark Mallon, Oort Douglas M Van, Robert J Shovlin, Steven C Jones and William Bonello.
View institutional ownership trends for NeoGenomics
.

Which institutional investors are selling NeoGenomics stock?

NEO stock was sold by a variety of institutional investors in the last quarter, including Scout Investments Inc., State of Alaska Department of Revenue, HighMark Wealth Management LLC, and Cutler Group LP. Company insiders that have sold NeoGenomics company stock in the last year include Bruce K Crowther, Douglas Matthew Brown, George Cardoza, Kathryn B Mckenzie, and Robert J Shovlin.
View insider buying and selling activity for NeoGenomics
or view top insider-selling stocks.

Which institutional investors are buying NeoGenomics stock?

NEO stock was bought by a variety of institutional investors in the last quarter, including Exchange Traded Concepts LLC, Lindbrook Capital LLC, and Crossmark Global Holdings Inc..
View insider buying and selling activity for NeoGenomics
or or view top insider-buying stocks.

How do I buy shares of NeoGenomics?

Shares of NEO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NeoGenomics' stock price today?

One share of NEO stock can currently be purchased for approximately $21.59.

How much money does NeoGenomics make?

NeoGenomics has a market capitalization of $2.66 billion and generates $444.45 million in revenue each year. The medical research company earns $4.17 million in net income (profit) each year or $0.36 on an earnings per share basis.

How many employees does NeoGenomics have?

NeoGenomics employs 1,700 workers across the globe.

What is NeoGenomics' official website?

The official website for NeoGenomics is www.neogenomics.com.

Where are NeoGenomics' headquarters?

How can I contact NeoGenomics?

NeoGenomics' mailing address is 12701 COMMONWEALTH DRIVE SUITE 9, FORT MYERS FL, 33913. The medical research company can be reached via phone at (239) 768-0600, via email at [email protected], or via fax at 239-690-4237.


This page was last updated on 1/22/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.